NT Mobile Menu

Search form


Samuel Pleasure, MD, PhD

Samuel Pleasure, MD, PhD

Samuel Pleasure, MD, PhD, is Professor of Neurology and Neuroscience at UCSF School of Medicine. He attended Penn for his MD and PhD (Neuroscience) and trained clinically at UCSF. His scientific interests are in brain development and the role of autoimmunity in causing CNS disease. He has numerous scientific publications and is an active clinician seeing patients in the MS clinic as well as attending at San Francisco General Hospital.

Posts by Author

Patients with juvenile myoclonic epilepsy appear to have modest cognitive defects and imaging abnormalities early on that are unlikely to be associated with anti-epileptic therapy. This is a clear departure from traditional teaching.

Serum testing for NMDAR and other autoantibodies is fraught with pitfalls, and careful clinical consideration is important.

If an anti-NMDAR patient has evidence of demyelination on MRI, look for other antibodies that may complicate the picture.

What emerged is that Devic’s is a distinct syndrome that results in widespread destructive lesions in the spinal cord that are not strictly demyelinating in their onset. Interesting questions remain.

Recent studies have suggested that H1N1 influenza might be the trigger for some patients, but a number of interesting questions remain.

How do we use Tysabri responsibly? How often should you screen patients taking the medication for the JC virus? What are the considerations for transitioning JC+ patients to another medication—and when is the best time to make the transition?

Samuel Pleasure, MD, PhD

Recent studies are showing that patients with autoimmune associated epilepsy may respond favorably to immunosuppression and that many of affected patients lack the full-fledged syndromes that have received so much attention.

By clicking Accept, you agree to become a member of the UBM Medica Community.